Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.730
-0.010 (-0.57%)
At close: Apr 2, 2026, 4:00 PM EDT
1.738
+0.008 (0.48%)
After-hours: Apr 2, 2026, 5:23 PM EDT

Coherus Oncology Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2591721603746251,228
Market Cap Growth
146.73%7.83%-57.30%-40.16%-49.14%-2.58%
Enterprise Value
141.5538.42301.77734.63908.931,226
Last Close Price
1.731.421.383.337.9215.96
PE Ratio
1.540.995.52-1.32-2.11-4.19
PS Ratio
6.154.086.051.452.963.76
PB Ratio
3.442.82-1.21-1.93-4.5412.56
P/TBV Ratio
3.322.73-1.20-1.62-4.4712.32
P/FCF Ratio
--1.24-7.81-2.14-2.59-31.71
P/OCF Ratio
--1.24-7.81-2.14-2.59-32.80
EV/Sales Ratio
3.360.9111.442.864.313.75
EV/EBITDA Ratio
--0.22-1.55-3.68-3.59-4.71
EV/EBIT Ratio
--0.21-1.51-3.62-3.54-4.65
EV/FCF Ratio
--0.28-14.76-4.20-3.77-31.67
Debt / Equity Ratio
0.630.63-2.03-2.47-3.464.25
Debt / EBITDA Ratio
-0.22-0.22-1.38-2.40-1.88-1.60
Debt / FCF Ratio
-0.28-0.28-13.12-2.74-1.97-10.73
Net Debt / Equity Ratio
-2.19-2.19-1.08-1.87-2.07-0.02
Net Debt / EBITDA Ratio
0.750.75-0.73-1.81-1.120.01
Net Debt / FCF Ratio
0.970.97-6.96-2.06-1.180.04
Asset Turnover
0.120.120.050.460.360.43
Inventory Turnover
3.743.740.263.141.831.41
Quick Ratio
1.361.360.881.142.173.27
Current Ratio
1.471.471.211.432.753.64
Return on Equity (ROE)
-473.47%-473.47%-17.52%143.81%1470.09%-151.62%
Return on Assets (ROA)
-51.25%-51.25%-37.04%-36.54%-44.28%-34.70%
Return on Invested Capital (ROIC)
2480.78%2480.78%-181.79%-122.75%-207.76%-209.70%
Return on Capital Employed (ROCE)
-127.78%-127.78%-86.17%-63.50%-60.01%-43.61%
Earnings Yield
64.80%100.70%18.12%-75.98%-47.47%-23.87%
FCF Yield
-53.42%-80.51%-12.81%-46.80%-38.61%-3.15%
Buyback Yield / Dilution
-2.26%-2.26%-21.65%-21.30%-2.89%9.63%
Total Shareholder Return
-2.26%-2.26%-21.65%-21.30%-2.89%9.63%
Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q